MYLAN FILES ANTITRUST DORYX® COMPLAINT

9 July 2012, Melbourne Australia: Mayne Pharma Group Limited (Mayne Pharma; ASX: MYX) today announced that Mylan Pharmaceuticals Inc. (Mylan), has filed an antitrust suit against Warner Chilcott LLC and certain of its related entities (Warner Chilcott), and Mayne Pharma (including its subsidiary Mayne Pharma International Pty Ltd) in the U.S. District Court for the Eastern District of Pennsylvania.

Mylan alleges that Mayne Pharma and Warner Chilcott have engaged in conduct that constrained generic competition for Doryx®, and seeks unspecified damages and attorney's fees. Mayne Pharma and Warner Chilcott are reviewing the complaint and intend to vigorously defend the litigation. Additionally, Mayne Pharma does not foresee incurring any material financial liabilities in relation to this action based on pre-existing contractual rights with Warner Chilcott.

As previously disclosed to the market, Mayne Pharma, together with Warner Chilcott have also filed an appeal with the U.S. Court of Appeals for the Federal Circuit in relation to the Doryx® non-infringement determinations handed down on 30 April 2012.

-ENDS-

For further information contact:
Scott Richards +61 8 8209 2410
Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

Mayne Pharma Profile:
Mayne Pharma Group Limited (Mayne Pharma) is an Australian specialist pharmaceutical company with an intellectual property portfolio built around the optimisation and delivery of oral dosage form drugs.

Mayne Pharma has a long and successful history of developing and commercializing improved pharmaceuticals and has launched and marketed numerous products through partnerships with licensees in various countries around the world. Mayne Pharma focuses on delivering to patients improved versions of existing drugs in order to advance safety, efficacy or ease of administration.

A technology driven company, Mayne Pharma has a significant product portfolio and pipeline, global reach through distribution partners in Australia, USA, Europe and Asia and a manufacturing facility based in Salisbury, South Australia that employs over 150 people on a 32 acre site. The facility also undertakes the manufacture of products under contract for third parties to TGA, FDA and EU regulatory guidelines.